Experimental and clinical results of application of antitumor vaccines obtained by means of bacterial metabolism.
By means of metabolic products of the AB-56 strain of Bac. mesentericus it was possible to produce specific antitumor vaccines which both in experimental and clinical conditions proved to have prophylactic and therapeutic effects. 60-100% of the animals prophylactically immunized with these vaccines became resistant to a subsequent injection of living virulent cells, the percentage depending on the number of immunizations. The employment of similar autovaccines in the treatment of relapses and metastases in humans resulted in a 56% five-year survival of patients operated on for gastric cancer, in contrast to a 28% five-year survival of those without any vaccination.
D000230:Adenocarcinoma / Q000601:surgery / Q000628:therapy*; D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D001410:Bacillus megaterium / Q000276:immunology*; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009368:Neoplasm Transplantation; D011817:Rabbits; D013274:Stomach Neoplasms / Q000601:surgery / Q000628:therapy*
D000951:Antigens, Neoplasm; D001428:Bacterial Vaccines